Oncolytics Biotech (NASDAQ:ONCY) Upgraded at Raymond James

Raymond James upgraded shares of Oncolytics Biotech (NASDAQ:ONCY) to a moderate buy rating in a research note issued to investors on Thursday morning,Zacks.com reports. Raymond James also issued estimates for Oncolytics Biotech’s Q4 2024 earnings at ($0.09) EPS, FY2024 earnings at ($0.32) EPS, Q1 2025 earnings at ($0.09) EPS and FY2025 earnings at ($0.34) EPS.

A number of other analysts also recently issued reports on ONCY. Leede Financial downgraded shares of Oncolytics Biotech from a “strong-buy” rating to a “moderate buy” rating in a report on Wednesday. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price target on shares of Oncolytics Biotech in a report on Thursday.

Oncolytics Biotech Trading Down 3.0 %

ONCY stock opened at $0.98 on Thursday. The stock has a market cap of $75.53 million, a P/E ratio of -3.63 and a beta of 1.69. The stock’s fifty day simple moving average is $1.09 and its two-hundred day simple moving average is $1.06. Oncolytics Biotech has a 1-year low of $0.84 and a 1-year high of $1.75.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Oncolytics Biotech stock. Virtu Financial LLC purchased a new stake in Oncolytics Biotech Inc. (NASDAQ:ONCY) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 51,889 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned approximately 0.07% of Oncolytics Biotech as of its most recent SEC filing. 6.82% of the stock is owned by institutional investors.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.